Ahmad Alwassia, MD
Critical Care Medicine · North Dartmouth, MANPI 1700149366
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 232 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AstraZeneca at 58.3% of the total. Reporting peaked in 2024 at $1,773 and has fallen 67.1% since, to $583 in 2025. Among critical care medicine clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 232 payments — averaging $22.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Electromed, Inc.$336
- E.r. Squibb & Sons, L.L.C.$220
- GSK$191
- Harmony Biosciences LLC$161
- Sanofi$159
- plus $1K from 19 others
What the payments were for
- Food & beverage$5,01697%
- Education$1553%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 136 | $3,014 |
| Electromed, Inc. | 21 | $336 |
| E.r. Squibb & Sons, L.L.C. | 11 | $220 |
| GSK | 9 | $191 |
| Harmony Biosciences LLC | 5 | $161 |
| Sanofi | 7 | $159 |
| Boehringer Ingelheim | 6 | $154 |
| Mylan Specialty L.p. | 7 | $150 |
| Covidien LP | 2 | $121 |
| United Therapeutics Corporation | 5 | $109 |
| Resmed Corp | 1 | $93 |
| Axsome Therapeutics, Inc. | 3 | $67 |
| Amgen | 3 | $46 |
| Baxter Healthcare | 2 | $42 |
| Viatris Specialty LLC | 2 | $40 |
| Philips North America LLC | 2 | $37 |
| Jazz Pharmaceuticals Inc. | 1 | $35 |
| Grifols USA, LLC | 1 | $35 |
| Boston Scientific | 2 | $35 |
| Inspire Medical Systems, Inc. | 1 | $28 |
| AbbVie | 1 | $22 |
| Novartis | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $19 |
| 3b Medical, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$322
- BREZTRI$322
- TEZSPIRE$192
- TUDORZA PRESSAIR$192
- SYMBICORT$129
How this compares
$5,172 in reported general payments places this provider in the 90th percentile of 158 critical care medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 155 | $144,054 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 115 | $109,017 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 43 | $28,545 |
| Spiriva RespimatTiotropium Bromide | 18 | $22,471 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $17,854 |
| Incruse ElliptaUmeclidinium Bromide | 34 | $15,061 |
| DuleraMometasone/Formoterol | 18 | $13,067 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $11,236 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $5,772 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 141 | $3,896 |
| Wixela InhubFluticasone Propion/Salmeterol | 14 | $3,781 |
| Ventolin HfaAlbuterol Sulfate | 41 | $2,377 |
| Montelukast Sodium | 29 | $386 |
| Prednisone | 46 | $257 |
| Azithromycin | 17 | $194 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $191 | $170,477222 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $3,014 | $155,290181 claims |
| Boehringer IngelheimSpiriva Respimat | $154 | $22,47118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 158 critical care medicine providers in Massachusetts.
Other critical care medicine in North Dartmouth
- Richard ChannickBoston$638K
- Ioana PrestonBurlington$544K
- Mark TidswellSpringfield$135K
- Benjamin MedoffBoston$98K
- Jerome CrowleyBoston$38K
- William McGeeSpringfield$32K
- Diana Espinoza BarreraBoston$17K
- Raghu SeethalaWeymouth$14K
- Catherine FioreBoston$13K
- Ilana KrummBoston$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.